Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00186277 | Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Mar 30, 2011 | clinicaltrials |
| NCT00330707 | Combined Use of BCG and Interferon Alpha in Bladder Cancer | completed | Phase 2 / Phase 3 | 140 | National University Hospital, SingaporeOTHER | 1 | Mar 4, 2011 | clinicaltrials |
| A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer |
| completed |
| Phase 2 |
| 54 |
| AstraZenecaINDUSTRY |
| 5 |
| Jan 12, 2011 |
| clinicaltrials |
| NCT00374868 | Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable) | completed | Phase 1 / Phase 2 | 59 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 4, 2010 | clinicaltrials |
| NCT00077974 | A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. | completed | Phase 2 | 106 | PfizerINDUSTRY | 1 | Oct 13, 2010 | clinicaltrials |
| NCT01176552 | Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer | completed | Phase 2 | 35 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT01182142 | Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients | completed | Phase 2 | 51 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT00003928 | Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 32 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 11, 2010 | clinicaltrials |
| NCT00006255 | Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases | completed | Phase 2 | 17 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 11, 2010 | clinicaltrials |
| NCT00848640 | Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma(MERITS) | completed | Phase 2 | 75 | Egyptian Foundation For Cancer ResearchOTHER | 1 | May 26, 2010 | clinicaltrials |
| NCT00118326 | Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2010 | clinicaltrials |
| NCT00004157 | Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00010283 | Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00101608 | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 15 | Mar 2, 2010 | clinicaltrials |
| NCT00254540 | Study of SU011248 in Patients With Advanced Kidney Cancer | completed | Phase 2 | 51 | PfizerINDUSTRY | 1 | Feb 23, 2010 | clinicaltrials |
| NCT00891748 | Safety Study on AdCD40L Gene Therapy for Bladder Cancer | completed | Phase 1 / Phase 2 | 12 | Uppsala UniversityOTHER | 1 | Jan 18, 2010 | clinicaltrials |
| NCT00089648 | SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma | completed | Phase 2 | 61 | PfizerINDUSTRY | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00017329 | PS-341 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 15, 2009 | clinicaltrials |
| NCT00034177 | Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium | completed | Phase 2 | 27 | Achieve Life SciencesINDUSTRY | 0 | Jun 4, 2009 | clinicaltrials |
| NCT00077688 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 44 | Achieve Life SciencesINDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00591188 | Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens | completed | Phase 2 | 49 | Kidney Cancer Research BureauOTHER | 1 | May 1, 2009 | clinicaltrials |
| NCT00226980 | A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma | completed | Phase 2 | 30 | Stanford UniversityOTHER | 1 | Apr 14, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00609401 | Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)(ROSORC) | completed | Phase 2 | 90 | Italian Trial in Medical OncologyOTHER | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00043407 | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00496301 | Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC(SOGUG-02-06) | completed | Phase 2 | 40 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Jan 14, 2009 | clinicaltrials |
| NCT00246974 | Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT | completed | Phase 2 | 125 | AstraZenecaINDUSTRY | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00425204 | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | completed | Phase 2 | 31 | AmgenINDUSTRY | 0 | Sep 15, 2008 | clinicaltrials |
| NCT00422786 | Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma | completed | Phase 2 | 10 | Thallion PharmaceuticalsINDUSTRY | 1 | Jul 15, 2008 | clinicaltrials |
| NCT00696579 | Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 64 | University Of PerugiaOTHER | 1 | Jun 12, 2008 | clinicaltrials |
| NCT00095186 | Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma | completed | Phase 2 | 40 | AgennixINDUSTRY | 1 | Apr 10, 2008 | clinicaltrials |
| NCT00059735 | A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma | completed | Phase 2 | 30 | Eisai Inc.INDUSTRY | 2 | Mar 5, 2008 | clinicaltrials |
| NCT00056173 | Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Aptose Biosciences Inc.INDUSTRY | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00393809 | Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 18 | Hebrew University of JerusalemOTHER | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00073112 | A Study of ABT-751 in Patients With Renal Cell Cancer | completed | Phase 2 | 60 | AbbottINDUSTRY | 2 | Nov 29, 2007 | clinicaltrials |
| NCT00191971 | 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen | completed | Phase 2 | 40 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 6, 2007 | clinicaltrials |
| NCT00073125 | Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 103 | AbbottINDUSTRY | 2 | Aug 15, 2007 | clinicaltrials |
| NCT00490880 | Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer | completed | Phase 2 | 2 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00491114 | Intravesical Chemotherapy Treatment of Superficial Bladder Cancer | completed | Phase 2 | 8 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00192049 | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | May 17, 2007 | clinicaltrials |
| NCT00054886 | Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer | completed | Phase 2 | 63 | PfizerINDUSTRY | 1 | May 7, 2007 | clinicaltrials |
| NCT00134186 | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer | completed | Phase 2 | 43 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 5, 2007 | clinicaltrials |
| NCT00191711 | Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00034593 | A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 3 | Jul 19, 2006 | clinicaltrials |
| NCT00035061 | A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2006 | clinicaltrials |
| NCT00343356 | Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder | completed | Phase 2 | 138 | LanZhou UniversityOTHER | 0 | Jun 22, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Mar 30, 2011source: clinicaltrials